NYC-based BioNeex secures $500K in seed funding. Leaders in the biopharmaceutical sector, including former Pfizer and Amgen executives, spearheaded the funding round.
The money will be used by the business to develop new products, one of which will be improving the BioNeex platform’s user experience.
Read also – CA-based Lilac Solutions Secures $145Million in Series C Round Funding
In order to directly facilitate licensing and co-development partnerships for preclinical and clinical-stage drug candidates, as well as investment deals, BioNeex offers an R&D business development platform for the biopharmaceutical industry. This platform is led by Chief Technology Officer Edgar Marukyan and Founder and CEO Dr. Smbat Rafayelyan.
Potential investors, licensing, and co-development partners can get the most recent data from drug candidate developers through BioNeex and get in touch with them directly.
Read also – CA-based Freenome Secures $254Million in Funding
Smbat Rafayelyan said: “Their investment in BioNeex will help us continue to provide new products, services and platform enhancements that improve how drug development companies, potential partners and investors interact via the BioNeex marketplace.“
About BioNeex
The first biopharma R&D business development platform, BioNeex is a two-sided drug candidate marketplace driven by artificial intelligence. It links venture capital firms, biotech startups, and pharmaceutical companies to enable investments, co-development collaboration agreements for preclinical and clinical-stage drug concepts, and licensing.
Read also – CA-based Point2 Technology Secures Additional $22.6Million in Series B Round Funding
